in the creation of “genome vessels” by Craig Venter and his team
(the latter innovation, which was publicized in March 2016, cost
a paltry 60 million dollars) open up the perspective of targeting
synthetic drugs directly at affected tissue, without the usual side
effects to the whole human system. Proteins on a chip will serve
as sensors in diagnostics. New biomaterials can be created as
implants, bone replacements, or as dialysis minilabs, if not as outright
kidneys. Industrial enzymes will help to replace fossil oilbased
chemical processes with biological processes. New minimal
organisms will emerge as building blocks for a new biological
diversity. Bio-machines will turn straw into biofuel, and will capture
carbon dioxide from the atmosphere. Our artificial evolution
will create living, surviving artificial cells and new biological species.